stockportfolio.pro
Collegium Pharmaceutical, Inc. (COLL)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Collegium Pharmaceutical, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.71M | $28.48M | $280.41M | $296.70M | $310.02M | $276.87M | $463.93M | $566.77M | $631.45M | $780.57M |
| Gross profit | $1.50M | $25.88M | $114.74M | $103.04M | $179.84M | $150.62M | $209.49M | $326.17M | $377.34M | $463.26M |
| Net income | $-94.18M | $-74.86M | $-39.13M | $-22.72M | $26.75M | $71.52M | $-25.00M | $48.16M | $69.19M | $62.87M |
| Net margin | -5504.1% | -262.9% | -14.0% | -7.7% | 8.6% | 25.8% | -5.4% | 8.5% | 11.0% | 8.1% |
Source: Collegium Pharmaceutical, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
What growth is priced into COLL stock?
At today's market cap of $1.13B, Collegium Pharmaceutical, Inc. is priced for free-cash-flow growth of about -18.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $327.58M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 30%/yr over the last five fiscal years and revenue 20.3%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 13 years of Collegium Pharmaceutical, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track COLL in your portfolio →
Collegium Pharmaceutical, Inc. financial history by metric
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc. — frequently asked questions
What is Collegium Pharmaceutical, Inc.'s revenue?
Collegium Pharmaceutical, Inc. (COLL) reported revenue of $780.57M for fiscal year 2025, up 23.6% from the prior year, according to its SEC filings.
Is Collegium Pharmaceutical, Inc. profitable?
Yes. COLL earned net income of $62.87M in fiscal 2025, a net margin of 8.1%.
What is COLL's P/E ratio?
Collegium Pharmaceutical, Inc. trades at a price-to-earnings ratio of about 16.8 based on the latest data in our nightly-refreshed cache.
How fast is Collegium Pharmaceutical, Inc. growing?
COLL's revenue grew at roughly 20.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Collegium Pharmaceutical, Inc. have?
As of fiscal year 2025, COLL carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Collegium Pharmaceutical, Inc.'s gross margin?
COLL's gross margin was 59.3% in fiscal 2025 — gross profit of $463.26M on revenue of $780.57M.
What is Collegium Pharmaceutical, Inc.'s market cap?
Collegium Pharmaceutical, Inc. (COLL) has a market capitalization of about $1.13B, based on the latest data in our nightly-refreshed cache.
When does Collegium Pharmaceutical, Inc.'s fiscal year end?
COLL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into COLL stock?
At today's market cap of $1.13B, Collegium Pharmaceutical, Inc. is priced for free-cash-flow growth of about -18.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $327.58M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 30%/yr over the last five fiscal years and revenue 20.3%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Collegium Pharmaceutical, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.